News

Study OverviewBrief SummarySystemic light chain amyloidosis (AL amyloidosis) is the most common type of systemic amyloidosis, with diverse clinical manifestations…

The U.S. Food and Drug Administration approved Attruby (acoramidis) for adults with cardiomyopathy of wild-type or variant (hereditary) transthyretin-mediated…

AccurKardia said it was granted a U.S. patent for its machine-learning-based algorithm that can identify cardiac amyloidosis from a standard 12-lead ECG. Use of ECG…

In people with transthyretin amyloid cardiomyopathy (ATTR-CM), the buildup of faulty transthyretin (TTR) protein in the heart may contribute to blood clots that…

At the European Society of Cardiology's Heart Failure Congress in Barcelona, ​​Bayer announced the results of new analyses of acoramidis in transthyretin amyloid…

AbstractBackground: The care of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) is often fragmented and routine datasets rarely capture real-world…

NAPLES, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives…

It has been a busy period for the amyloidosis treatment field. In April, Danish drugmaker Novo Nordisk (NOV: N) received US Food and Drug Administration (FDA) Fast…

AbstractPurposeScintigraphy using 99mTc-labeled bone-seeking tracers is a cornerstone in the non-invasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM…

Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognized cause of heart failure and conduction disease in older adults. Resulting from either…